hotspot -WSS

hotspot

author：knowledge 2025-10-02 22:23:49 - browse：83

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Doctors push to include dialysis machines in emergency stockpile

hotspot

WSS

How CRISPR works, explained in two minutes

Dozens dead from Maui wildfires: What we know about the victims

After Optum profits sink, UnitedHealth makes changes

Feed a cold, starve a fever? Here’s what science says

What to know about the judge who will handle the Trump case

Surge in Apellis stock fueled by confidence in safety of its eye drug

hotspot

hotspot

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Illumina slashes 2023 revenue projections yet again

How one medical school became remarkably diverse

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

State Dept. review finds Biden bears some blame for Afghanistan failures

Treatments for cramps don't cut it. Why aren't there better options?

Anesthesiologist group: stop taking Ozempic before surgery

Montana youths win climate lawsuit against state for promoting fossil fuels

State Dept. review finds Biden bears some blame for Afghanistan failures

Be careful with at

hotspot

Montana youths win climate lawsuit against state for promoting fossil fuels

Biden administration begins canceling student loan debt for 804,000 borrowers

Kansas bar where gunfire wounded 9 last month closes permanently

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Pennsylvania man bitten on the head by bear during attack in his garage

Megan Rapinoe shares emotional post following US Women's World Cup exit

leisure time

hotspot

Wikipedia

explore